Martins - Clínica Médica (Volume 5)_Parte56

Prévia do material em texto

CLÍNICA MÉDICA ! DOENÇAS ENDÓCRINAS E METABÓLICAS46
16. Cavallo A, Richards GE, Busey S, Michaels SE. A simplified gonadotrophin-re-
leasing hormone test for precocious puberty. Clin Endocrinol 1995; 42:641-6.
17. Eckert KL, Wilson DM, Bachrach LK, et al. A single-sample, subcutaneous gona-
dotropin-releasing hormone test for central precocious puberty. Pediatrics 1996;
97:517-9.
18. Brito VN, Latronico AC, Arnhold IJ, Mendonca BB. A single luteinizing hor-
mone determination 2 hours after depot leuprolide is useful for therapy moni-
toring of gonadotropin-dependent precocious puberty in girls. J Clin Endocri-
nol Metab 2004; 89:4338-42.
19. Brito VN, Latronico AC, Arnhold IJ, et al. Treatment of gonadotropin depen-
dent precocious puberty due to hypothalamic hamartoma with gonadotropin
releasing hormone agonist depot. Arch Dis Child 1999; 80:231-4.
20. Jung H, Ojeda SR. Pathogenesis of precocious puberty in hypothalamic hamar-
toma. Horm Res 2002; 57(Suppl 2):31-4.
21. Parker KL, Baens-Bailon RG, Lee PA. Depot leuprolide acetate dosage for sexual
precocity. J Clin Endocrinol Metab1991; 73:50-2.
22. Cook JS, Doty KL, Conn PM, Hansen JR. Assessment of depot leuprolide ace-
tate dose-adequacy for central precocious puberty. J Clin Endocrinol Metab
1992; 74:1206-9.
23. Witchel SF, Baens-Bailon RG, Lee PA. Treatment of central precocious puberty:
comparison of urinary gonadotropin excretion and gonadotropin-releasing
hormone (GnRH) stimulation tests in monitoring GnRH analog therapy. J Clin
Endocrinol Metab 1996; 81:1353-6.
24. Klein KO, Baron J, Barnes KM, Pescovitz OH, Cutler Jr GB. Use of an ultra-
sensitive recombinant cell bioassay to determine estrogen levels in girls with
precocious puberty treated with a luteinizing hormone-releasing hormone
agonist. J Clin Endocrinol Metab 1998; 83:2387-9.
25. Lawson ML, Cohen N. A single sample subcutaneous luteinizing hormone
(LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppres-
sion in children with central precocious puberty receiving LHRH agonists. J
Clin Endocrinol Metab 1999; 84:4536-40.
26. Volta C, Regazzi C, Ndaka J, Vitale R, Bernasconi S. Combined therapy with lu-
teinizing hormone releasing hormone agonist (LHRHa) and growth hormone
(GH) in central precocious puberty. Acta Biomed 2005; 76(2):73-8.
27. D’Alva C, Brito VN, Palhares HM, Carvalho FM, Arnhold IJP, Mendonça BB, et
al. A single somatic activating Asp578His mutation of the luteinizing hormone
receptor causes Leydig cell tumour in boys with gonadotropin-independent
precocious puberty. Clin Endocrinol 2006; 65(3):408-10. 
28. Fragoso MC, Latronico AC, Carvalho FM, et al. Activating mutation of the sti-
mulatory G protein (gsp) as a putative cause of ovarian and testicular human
stromal Leydig cell tumors. J Clin Endocrinol Metab 1998; 83:2074-8.
29. Kalantaridou SN, Chrousos GP. Clinical review 148: Monogenic disorders of
puberty. J Clin Endocrinol Metab 2002; 87:2481-94.
30. Latronico AC, Shinozaki H, Guerra Jr G, Pereira MA, Lemos Marini SH, Bap-
tista MT, et al. Gonadotropin-independent precocious puberty due to luteini-
zing hormone receptor mutations in Brazilian boys: a novel constitutively acti-
vating mutation in the first transmembrane helix.J Clin Endocrinol Metab 2000
Dec; 85(12):4799-805.
31. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Ac-
tivating mutations of the stimulatory G protein in the McCune-Albright syn-
drome. N Engl J Med 1991; 325:1688-95.
32. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH. Effect of pa-
midronate treatment in children with polyostotic fibrous dysplasia of bone. J
Clin Endocrinol Metab 2003; 88:4569-75.
33. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH. Tamoxifen
treatment for precocious puberty in McCune-Albright syndrome: a multicenter
trial. J Pediatr 2003; 143:60-6.
34. Feuillan P, Merke D, Leschek EW, Cutler Jr GB. Use of aromatase inhibitors in
precocious puberty. Endocr Relat Cancer 1999; 6:303-6.
35. Mainieri AS, Elnecave RH. Usefulness of the free alpha-subunit to diagnose hy-
pogonadotropic hypogonadism. Clin Endocrinol 2003; 59:307-13.
36. Degros V, Cortet-Rudelli C, Soudan B, Dewailly D. The human chorionic gona-
dotropin test is more powerful than the gonadotropin-releasing hormone ago-
nist test to discriminate male isolated hypogonadotropic hypogonadism from
constitutional delayed puberty. Eur J Endocrinol 2003; 149:23-9.
37. Dunkel L, Wickman S. Novel treatment of delayed male puberty with aromata-
se inhibitors. Horm Res 2002; 57(Suppl 2):44-52.
38. Silveira LF, MacColl GS, Bouloux PM. Hypogonadotropic hypogonadism. Se-
min Reprod Med 2002; 20:327-338.
39. Achermann JC, Ozisik G, Meeks JJ, Jameson JL. Genetic causes of human re-
productive disease. J Clin Endocrinol Metab 2002; 87:2447-54.
40. Bondy CA, Turner Syndrome Study Group. Care of girls and women with Tur-
ner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endo-
crinol Metab 2007; 92(1):10-25.
41. Swerdlow AJ, Higgins CD, Schoemaker MJ, Wright AF, Jacobs PA on behalf of
the United Kingdom Clinical Cytogenetics Group. Mortality in patients with
Klinefelter syndrome in Britain: a cohort study. J Clin Endocrinol Metab 2005;
90:6516-22.
	Martins - Clínica Médica (Volume 5)